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Background: The primary objective of this study was to evaluate long-term (24-week) safety of eszopiclone in
elderly and nonelderly Japanese patients with chronic insomnia. The secondary objectives were to evaluate short-
term (4-week) efficacy and to assess for rebound insomnia or dependence after long-term treatment.
Methods: Patients (n = 164 elderly; n = 161 nonelderly), with or without psychiatric comorbidities, were randomized
to receive low-dose (1 mg, elderly; 2 mg, nonelderly) or high-dose (2 mg, elderly; 3 mg, nonelderly) eszopiclone.
The safety evaluation included adverse events, vital signs, clinical laboratory parameters, and electrocardiogram.
Efficacy was assessed using patient reports of sleep latency (SL), total sleep time (TST), wake time after sleep onset
(WASO), number of awakenings (NA), quality of sleep, depth of sleep, daytime sleepiness, daytime ability to
function, and the 36-item Short Form (SF-36) Health Survey.
Results: The rate of adverse events was 81.5% in the 1-mg elderly group, 79.5% in the 2-mg elderly group, 82.1% in
the 2-mg nonelderly group, and 87.0% in the 3-mg nonelderly group. Dysgeusia was the most common adverse
event and was dose-related. Of 12 serious adverse events, none were considered by the investigator to be related
to study medication. No rebound insomnia was observed. Eszopiclone significantly improved SL, TST, WASO, NA,
and daytime sleepiness and function from baseline to Week 4, irrespective of age and psychiatric comorbidity.
Improvements were also observed in SF-36 Mental Health Component scores in elderly and nonelderly patients
with psychiatric comorbidities.
Conclusions: Irrespective of age, eszopiclone appeared safe as administered in this study for 24 weeks. Eszopiclone
improved sleep variables in insomnia patients with and without psychiatric disorders and health-related quality of
life in those with psychiatric disorders.
Trial registration: ClinicalTrials.gov #NCT00770692; http://clinicaltrials.gov/ct2/show/NCT00770692.
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Epidemiologic surveys from different countries suggest
that 30% of adults have 1 or more symptoms of insom-
nia [1], and an estimated 10% of individuals exhibit
symptoms of functional impairment during the day that
is consistent with insomnia [2]. In the Japanese popula-
tion, insomnia affects 17.3% to 22.3% of men and 20.5%
to 21.5% of women [3]. Psychotropic medications are
often used for management of insomnia [4]. These medi-
cations, however, may be associated with an increased
risk of falls among the elderly [5]. Eszopiclone is an (S)-
isomer of zopiclone that is structurally classified as a
nonbenzodiazepine hypnotic [6,7]. In 2004, eszopiclone
was approved by the US Food and Drug Administration
for the treatment of insomnia in elderly and nonelderly
adults [6,8]. The clinical studies used for registration in
the United States included both short- and long-term
studies but did not include long-term studies in elderly
patients [9-13]. Overall outcomes in these studies
showed that eszopiclone significantly reduced sleep la-
tency (SL), increased total sleep time (TST), reduced
wake time after sleep onset (WASO), and was generally
well tolerated compared with placebo [8-13].
Increasing age has been identified as a risk factor for
insomnia. As the population ages, the number of elderly
patients with insomnia is expected to increase, along
with the need for safe and effective treatment options.
Insomnia in elderly patients often presents comorbidly
with medical or psychiatric conditions that usually re-
quire chronic therapy [14]. In a 12-week study of elderly
patients (N= 388) with either primary or comorbid
chronic insomnia, patient-reported sleep and daytime
function significantly improved following treatment with
eszopiclone compared with placebo, with no evidence of
rebound insomnia or withdrawal symptoms after treat-
ment discontinuation [15]. The rates of dizziness (4.1%
and 1.5%) and falls (1.0% and 0.5%) were relatively low
in patients receiving eszopiclone and placebo, respect-
ively, and eszopiclone was generally well tolerated and
safe in this patient population [15]. Assessment of the
tolerability, safety, and efficacy of eszopiclone beyond
12 weeks has not been reported in elderly patients.
Eszopiclone has been shown to be efficacious for pri-
mary insomnia in both elderly [12,13,15] and nonelderly
patients [9,11,16,17]. Furthermore, the effects of eszopi-
clone on sleep variables and comorbid conditions were
reported in nonelderly patients with insomnia comorbid
with depression, major depressive disorder, and general-
ized anxiety disorder [18-20]. No study has compared
treatment of eszopiclone for insomnia in patients with
and without psychiatric comorbidities. Although US
studies have established the safety and efficacy of eszopi-
clone in elderly and nonelderly adults with chronic in-
somnia [9,11-13,15-17], there have been no reports onthe safety and efficacy of eszopiclone in Japanese
populations.
The primary objective of the current study was to
evaluate the safety of eszopiclone, administered over
24 weeks, in Japanese elderly and nonelderly patients
with chronic insomnia. Assessment of safety included
adverse events, vital signs, clinical laboratory parameters,
electrocardiogram (ECG), and Questionnaire of Drug
Dependence. Secondary objectives were to evaluate the
efficacy of eszopiclone over 4 weeks in patients with in-
somnia with or without psychiatric disorders and to
evaluate the presence or absence of sleep rebound and
dependence after long-term treatment with eszopiclone.
Measures of efficacy included SL, TST, WASO, number
of awakenings (NA), quality of sleep, depth of sleep, day-
time sleepiness, daytime ability to function, and the 36-
item Short Form (SF-36) Health Survey. When this
study was planned, a placebo arm for chronic insomnia
did not seem to be acceptable from an ethical standpoint
and in light of the medical environment in Japan. The
safety of eszopiclone instead was evaluated by compari-
son between pre- and post-treatment data.
Methods
This multicenter, randomized, double-blind, parallel-
group study was conducted at 46 sites in Japan from Oc-
tober 2008 to May 2010. The protocol was approved by
local institutional review boards, and the study was con-
ducted in accordance with the principles of the Declar-
ation of Helsinki and Japan Good Clinical Practice. All
patients signed written informed consent prior to study
entry.
Patient selection
Outpatients 20 to 84 years of age seeking evaluation and
treatment for their sleep difficulties were considered eli-
gible for study entry when all of the following inclusion
criteria were met: (1) presence of primary insomnia, as
diagnosed by the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, Text Revision (DSM-
IV-TR) [21], or insomnia associated with a physical or
psychiatric disorder; (2) presence of reported symptoms
with SL ≥30 minutes on 3 or more nights per week and
TST ≤390 minutes on 3 or more nights per week for
4 weeks or more prior to screening; and (3) presence of
symptoms with SL ≥30 minutes on 3 or more nights (in-
cluding at least 2 consecutive nights) and TST ≤390
minutes on 3 or more nights (including at least 2 con-
secutive nights) as recorded in the patient self-report
sleep diary during the screening period. The threshold of
TST ≤390 minutes and the criterion of 2 consecutive
nights were used to ensure that the patient population
had a level of insomnia severity likely to show a treat-
ment effect.
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criteria: (1) risk of suicide, manic episode, post-
traumatic stress disorder (PTSD), history of or current
alcohol dependence or abuse, history of or current drug
dependence or abuse, anorexia nervosa, bulimia nervosa,
or antisocial personality disorder, as diagnosed by the
Mini-International Neuropsychiatric Interview (M.I.N.I.)
Japanese version 5.0.0; (2) drug-induced insomnia; (3)
primary sleep disorders other than primary insomnia
(eg, circadian rhythm disorder, restless leg syndrome,
periodic limb movement, sleep apnea); (4) severely dis-
turbed sleep by chronic pain, fever, diarrhea, frequent
urination, or coughing; (5) organic psychiatric disorder;
(6) suicidal ideation or attempt in the past 5 years; (7)
clinically severe dysfunction of the liver, kidney, cardio-
vascular system, or hematologic system or presence of a
malignant tumor; and (8) pregnancy or breast-feeding.
The restricted concomitant medications from 2 weeks
before to 4 weeks after starting eszopiclone administra-
tion included sedative hypnotics, anxiolytics not indi-
cated for insomnia, neurologic disease medications,
antiepileptics, Parkinson’s disease medications, antihista-
mines, analgesics, adrenal corticosteroids, bronchovaso-
dilators, melatonin, oriental medicines indicated for
insomnia, and herbal preparations or supplements used
for insomnia. The prohibited concomitant medications
from Day −10 to the end of study included sedative hyp-
notics other than eszopiclone, anxiolytics indicated for
insomnia, and potent inhibitors and inducers of cyto-
chrome P450 isoenzyme 3A4.Study procedures
The study consisted of 10 visits and 4 periods: the
screening period (Week −1; baseline), the first treatment
period (Weeks 1 to 4), the second treatment period
(Weeks 5 to 24), and the follow-up period (Week 25)
(Figure 1). At Day −7, patients signed written informed
consent, had their baseline characteristics (demograph-
ics, medications, and sleep, medical, and psychiatric his-
tories) recorded, and completed all other screeningFigure 1 Summary of study schematic from screening through study
Adverse events were collected from Weeks 1 to 25. Sleep variables were ob
Weeks −1, 4, 12 and 24.procedures, including vital signs, ECG, and clinical la-
boratory tests.
Patients who met inclusion criteria to enter into the
screening period were instructed to complete a self-
report sleep diary for 1 week. Patients used the diary to
record various sleep parameters, such as SL, TST, and
WASO. At Day 0, SL and TST for the previous 7 days
were assessed to judge the eligibility for study treatment.
The principal investigators and sub-investigators were
able to make a clinical diagnosis of primary insomnia,
insomnia associated with a physical disorder, or insom-
nia associated with a psychiatric disorder by taking
underlying physical conditions and psychiatric condi-
tions into consideration.
Drug allocation was performed by stratified block
randomization with 4 strata (elderly patients with psy-
chiatric disorders, elderly patients without psychiatric
disorders, nonelderly patients with psychiatric disorders,
nonelderly patients without psychiatric disorders). A
third-party drug randomization manager randomly
assigned the study medications to the eszopiclone 1-mg
group and the 2-mg group for each of the 2 elderly pa-
tient strata and to the eszopiclone 2-mg group or the 3-
mg group for each of the 2 nonelderly patient strata,
according to the treatment allocation table (key code
list) prepared by him/herself. The drug randomization
manager sealed drug codes immediately after randomiz-
ing patients and kept the drug codes until code-break.
Eligible patients with or without a comorbid psychi-
atric disorder were randomized by a third-party enroll-
ment center in a double-blind manner to 1 mg or 2 mg
eszopiclone (elderly patients, 65 to 84 years of age) or to
2 mg or 3 mg eszopiclone (nonelderly patients, 20 to
64 years of age). The use of different doses for none-
lderly (2 mg or 3 mg) and elderly patients (1 mg or
2 mg) was based on the pharmacokinetic profile of eszo-
piclone in studies of healthy subjects and on the findings
of previous clinical studies. Study medication was dis-
pensed at the study site with instructions on proper ad-
ministration and was self-administered by patients at
home. Patients took the assigned dose of eszopiclone atcompletion. Visits 6, 7, and 8 were conducted at 4-week intervals.
tained at Week −1 (baseline) and Weeks 1 to 4. SF-36 was assessed at
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out a self-report diary to assess sleep variables every day
during the first treatment period.
An uptitration was permitted for patients whose in-
somnia did not improve after 4 weeks of treatment with
low-dose eszopiclone. At the end of the first treatment
period (Week 4), the option of a 1-mg uptitration for
the second treatment period was evaluated for patients
meeting all of the following criteria: (1) no improvement
in SL or TST when comparing values at Week 4 and
baseline (ie, baseline SL ≤Week 4 SL, baseline TST ≥
Week 4 TST), (2) patient rating of “not changed” or
“worsened” on the global impression of overall improve-
ment of sleep, and (3) investigators’ judgment regarding
the safety of the dose increase. Patients who were
already taking the maximum dose (ie, 2 mg in the eld-
erly group and 3 mg in the nonelderly group) received
an additional 1-mg placebo tablet, and eligible patients
who had been treated initially with the lower dose of
eszopiclone (ie, 1 mg in the elderly group and 2 mg in
the nonelderly group) received an additional 1-mg eszo-
piclone tablet during the second treatment period.
Patients not eligible for uptitration continued to receive
their previous dose of study drug. Although patients and
investigators remained blinded to assigned dose, the
study investigator may have apprehended the dose given
after dose escalation.
Patients underwent scheduled examinations at all vis-
its and clinical laboratory tests at Weeks −1 (screening),
4, 8, 12, 16, and 20 and at Week 24 or final visit due to
early discontinuation. The investigators collected infor-
mation on adverse events from the time of the first dose
of eszopiclone and determined the relationship of all
reported adverse events as “related” or “not related” to
administration of eszopiclone. The follow-up period
lasted for 1 week from the end of the treatment period
or the day on which treatment was discontinued. During
the follow-up period, post-treatment safety, including
sleep rebound and dependency, was evaluated.
Study assessments
Adverse events were recorded at all study visits except
screening and were rated by study investigators for in-
tensity (mild, moderate, severe), seriousness, and rela-
tionship to study medication (unrelated, possibly related,
probably related). Vital signs, including blood pressure
and heart rate, were collected at Week −1 through the
final visit, and clinical laboratory assessments (including
hematology, blood biochemistry, and urinalysis) were
performed at screening and Week 4 through the final
visit. An ECG was obtained at screening and repeated at
Week 4 and at the final visit. The Questionnaire of Drug
Dependence was administered at the end of the follow-
up period (Week 25 or the week following the final visit)[22]. Rebound insomnia was defined as worsening in SL,
TST, or WASO after eszopiclone discontinuation com-
pared with baseline and was assessed at the follow-up
visit using a patient-reported sleep diary. Worsening was
defined as an increase in median SL or WASO or a de-
crease in median TST at follow-up compared with
baseline.
Efficacy assessments were the change in patient-
reported data from baseline to Week 4 for SL, TST,
WASO, NA, quality of sleep, depth of sleep, daytime
sleepiness, and daytime ability to function. Quality of
sleep, depth of sleep, and daytime ability to function
were assessed based on the patient-reported sleep diary
using a numeric rating scale, with scores ranging from 0
(poor) to 10 (excellent); daytime sleepiness was similarly
rated and was scored from 0 (very sleepy) to 10 (wide
awake). Change from baseline to Week 24 on the SF-36
Health Survey Version 2-Japanese Version was assessed
to evaluate health-related quality of life.Statistical methods
The study was powered at N= 320 to achieve a >80%
probability of detecting ≥1 adverse event at a 0.5% rate
and to meet the criteria for safety evaluation in accord-
ance with the International Conference on
Harmonization of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use (ICH E1) guide-
line, The Extent of Population Exposure to Assess
Clinical Safety for Drugs Intended for Long-term Treat-
ment of Non-Life-Threatening Conditions.
The safety analysis population included patients who
received ≥1 dose of study medication and ≥1 safety
evaluation. The efficacy analysis population comprised
all patients who had ≥1 dose of study medication and ≥1
efficacy evaluation. Most statistical analyses were per-
formed using SAS software (Version 9.1.3). All statistical
tests were conducted at the 15% (2-tailed) significance
level for homogeneity of background among each alloca-
tion and at the 5% (2-tailed) significance level for com-
parison of other evaluation items.
For continuous demographic and baseline variables,
summary statistics were calculated for elderly and none-
lderly patients in each dose group. The number and pro-
portion of patients per subgroup were calculated
according to elderly and nonelderly groups for ordered
categorical variables and categorical variables. A t-test
was performed for continuous variables and Fisher exact
test for categorical variables to confirm the homogeneity
of stratification factors (ie, 1 mg/2 mg in elderly patients
and 2 mg/3 mg in nonelderly patients; 1 mg/2 mg with
psychiatric disorders in elderly patients, 1 mg/2 mg
without psychiatric disorders in elderly patients, 2 mg/
3 mg with psychiatric disorders in nonelderly patients,
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lderly patients).
The number of adverse events, the number of patients
with adverse events, and adverse event rates were
obtained by group for elderly and nonelderly patients
with and without psychiatric disorders. For summaries
of adverse event rates, the number of patients who
reported ≥1 adverse event and the percentage of patients
in the safety analysis set were classified according to the
Medical Dictionary for Regulatory Activities (Japanese
version 13.0), system organ class, and preferred term as
well as by the investigator’s assessment of relationship to
drug and severity. For blood pressure, heart rate, and
clinical laboratory assessments, summary statistics of
data and changes at each evaluation time were calcu-
lated by group for continuous variables, whereas fre-
quency and percentage were calculated for categorical
variables. The frequency distribution of presence/ab-
sence of abnormal changes and the percent change were
calculated in each group (elderly and nonelderly, with orFigure 2 Patient disposition. aRandomization and the first administration
than 1 reason for study discontinuation; cDuring the week after discontinue
disorders; n2 = number of patients without psychiatric disorders.without psychiatric disorders) for abnormal changes in
blood pressure, heart rate, clinical laboratory tests, and
ECG parameters. For each item of the Questionnaire of
Drug Dependence, the frequency distribution and per-
centage were calculated for elderly and nonelderly
patients with and without psychiatric disorders.
Summary statistics for sleep variables (SL, TST,
WASO, and NA) were calculated by dose group for eld-
erly and nonelderly patients with and without psychiatric
disorders. For sleep variables (SL, TST, WASO, and
NA), the median of 7 days in the week of Weeks −1
(baseline), 1, 2, 3, and 4 was used as the representative
value for subgroups (ie, elderly and nonelderly with and
without psychiatric disorders). For statistical testing in
each subgroup, paired t tests (using log-transformed
data) were performed to compare Weeks 1 to 4 with
baseline. An analysis of variance model with stratifica-
tion for presence/absence of psychiatric disorders was
used for inter-group comparisons (1 mg vs 2 mg in eld-
erly patients; 2 mg vs 3 mg in nonelderly patients). Forof eszopiclone were performed on Day 0; bPatients could have more
d intervention. n1 = number of patients with comorbid psychiatric
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daytime ability to function, summary statistics were cal-
culated and paired t tests were performed to compare
Weeks 1 to 4 with baseline. Summary statistics were cal-
culated for subscale and summary score of the SF-36 for
elderly and nonelderly patients with and without psychi-
atric disorders. The SF-36 scores were transformed to
norm-based scorings representing the national standard
value of Japanese people (mean, 50; standard deviation
[SD], 10). The norm-based scorings at Week 24 or final
visit were compared with baseline using paired t tests,
with the last observation carried forward (LOCF). Be-
cause the safety evaluation was the primary objective of
the study, adjustment for multiple comparisons was not
performed.
To assess potential rebound insomnia, SL, TST, and
WASO in the follow-up period (Week 25) were com-
pared with baseline using paired t tests of log-
transformed data. Rebound insomnia was considered to
have occurred if the sleep parameters clearly deterio-




Of 369 patients screened, 164 elderly patients (81 with
psychiatric disorders, 83 without psychiatric disorders),
and 161 nonelderly patients (80 with psychiatric disor-
ders, 81 without psychiatric disorders) were randomized
to receive eszopiclone (Figure 2). All of the 164 elderly
patients and the 161 nonelderly patients who were en-
rolled in the treatment period were included in the
safety analysis set. The efficacy evaluation set included
all of the elderly and nonelderly patients who were en-
rolled in the treatment period, excluding 1 elderly pa-
tient in the 1-mg group (with psychiatric disorders) who
had no evaluable efficacy data. A total of 143 (87.2%)
patients in the elderly group and 136 (84.5%) patients in
the nonelderly group completed treatment with eszopi-
clone. Reasons for discontinuation are described in
Figure 2.
Demographics and baseline values for sleep variables
were similar in each subgroup (Table 1). There were no
statistically significant (P< 0.15) differences in baseline
sleep variables between patients assigned each of the 2
doses of eszopiclone, with the following exceptions: TST
for 2 mg versus 3 mg in nonelderly patients with psychi-
atric disorders (mean, 296.5 vs 315.3 min; P< 0.15), and
TST for 2 mg versus 3 mg in nonelderly patients without
psychiatric disorders (284.7 vs 301.6 min; P< 0.15).
Approximately half of enrolled patients had psychi-
atric disorders (49.4% of elderly patients and 49.7% of
nonelderly patients). The most common psychiatric dis-
orders among patients with insomnia associated with apsychiatric disorder were major depressive disorder,
generalized anxiety disorder, and dysthymic disorder
(Table 2). In insomnia patients without psychiatric disor-
ders, 76 of 83 elderly patients and 80 of 81 nonelderly
patients had a diagnosis of primary insomnia. Seven eld-
erly patients and 1 nonelderly patient had a diagnosis of
insomnia associated with physical disorders.
Among patients with insomnia and comorbid psychi-
atric disorders, the most common concomitant medica-
tions were psychoneurotics, anxiolytics, and peptic
ulcer medications (Table 3). The most common con-
comitant medications among those without psychiatric
disorders were analgesics, antipruritics, astringents, anti-
inflammatory agents, antihypertensives, and antihyperli-
pidemic agents.
Treatment compliance
Most elderly patients and all nonelderly patients had an
overall treatment compliance rate of >70%, measured as
the number of days on which the patient took study
medication since the previous assessment. Treatment
compliance rates through Week 4 of the treatment
period (the day of dose escalation judgment) were >70%
for the majority of elderly patients and for all nonelderly
patients. No differences in treatment compliance were
observed between treatment groups or between groups
with and without psychiatric disorders.
Safety
The safety analysis set included 164 elderly patients and
161 nonelderly patients. Overall, 81.5% of elderly
patients in the 1-mg group and 79.5% of those in the 2-
mg group reported at least 1 adverse event. The most
frequently reported adverse events in this group were
dysgeusia and nasopharyngitis (Table 4). The rate of ad-
verse events was 79.5% (1-mg group) and 81.0% (2-mg
group) for patients with psychiatric disorders and was
83.3% (1-mg group) and 78.0% (2-mg group) in patients
without psychiatric disorders. In nonelderly patients, the
rate of adverse events was 82.1% in the 2-mg group and
87.0% in the 3-mg group. The most common adverse
events were similar to those in elderly patients (Table 4).
Among nonelderly patients, ≥1 adverse event was
reported by 79.1% (2-mg group) and 91.9% (3-mg group)
of patients with psychiatric disorders and by 85.4% (2-
mg group) and 82.5% (3-mg group) of patients without
psychiatric disorders, respectively. Overall, no adverse
events occurred at a substantially higher rate among the
elderly and nonelderly populations in patients with psy-
chiatric disorders versus those without psychiatric disor-
ders. Overall, 5 adverse events led to discontinuation by
5 elderly patients and 9 adverse events led to discontinu-
ation by 8 nonelderly patients. Four adverse events in
elderly patients (anxiety, ECG abnormality, headache,
Table 1 Demographic characteristics and baseline values for sleep variables
Characteristic Elderly Elderly Nonelderly Nonelderly
1 mg 2 mg 2 mg 3 mg
Witha Withoutb Witha Withoutb Witha Withoutb Witha Withoutb
(n = 38) (n = 42) (n = 42) (n = 41) (n = 43) (n =41) (n = 37) (n = 40)
Age, y, mean (SD) 71.5 (5.0) 69.5 (3.9) 70.3 (5.1) 71.0 (4.4) 37.3 (10.7) 43.0 (10.1) 37.6 (9.1) 45.9 (12.2)
Sex, n (%)
Male 20 (52.6) 15 (35.7) 20 (47.6) 14 (34.1) 11 (25.6)* 18 (43.9) 22 (59.5) 19 (47.5)
Female 18 (47.4) 27 (64.3) 22 (52.4) 27 (65.9) 32 (74.4)* 23 (56.1) 15 (40.5) 21 (52.5)
Body mass index, kg/m2, mean (SD) 22.8 (3.4) 23.1 (3.1) 23.1 (3.3) 23.5 (3.3) 22.6 (4.2) 24.0 (4.2) 23.3 (4.0)† 22.5 (3.2)
Sleep latency, min
Mean (SD) 63.3 (44.0) 67.4 (37.4) 71.8 (49.6) 69.7 (45.1) 78.5 (62.8) 64.8 (41.3) 65.7 (46.0) 62.4 (38.9)
Median 60.0 60.0 60.0 60.0 60.0 60.0 60.0 55.0
Total sleep time, min
Mean (SD) 317.6 (77.1) 311.1 (70.4) 310.2 (67.2) 305.6 (52.4) 296.5 (46.8){ 284.7 (40.6)† 315.3 (60.5) 301.6 (54.9)
Median 330.0 310.0 330.0 300.0 300.0 290.0 330.0 300.0
Wake time after sleep onset, min
Mean (SD) 66.7 (56.9) 57.1 (48.1) 65.6 (63.0) 72.1 (63.6) 51.7 (41.5) 54.9 (42.6) 40.8 (40.5) 43.8 (41.6)
Median 60.0 40.0 35.0 50.0 40.0 60.0 30.0 33.8
a Insomnia with comorbid psychiatric disorders.
b Insomnia without comorbid psychiatric disorders.
*P< 0.01 vs nonelderly patients with psychiatric disorders receiving 3 mg eszopiclone.
†P< 0.05 vs nonelderly patients without psychiatric disorders receiving 3 mg eszopiclone.
{P< 0.05 vs nonelderly patients with psychiatric disorders receiving 3 mg eszopiclone.
SD= standard deviation.
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laboratory value, dysgeusia, gastric ulcer, malaise, som-
nolence) were judged by the investigator to be possibly
related to study medication. Adverse events leading to
discontinuation but assessed by investigators as unre-
lated to study medication included appendicitis, bone
fracture, depression (n = 2), and urticaria,
The only adverse event considered by the investigator to
be at least possibly related to study drug with a rate of
≥5% in elderly patients was dysgeusia (18.5% in the 1-mg
group and 27.7% in the 2-mg group). In nonelderlyTable 2 Comorbid psychiatric disorders in insomnia




(n = 81) (n = 80)
Major depressive disorder 49 (60.5) 59 (73.8)
Generalized anxiety disorder 11 (13.6) 6 (7.5)
Dysthymic disorder 10 (12.3) 7 (8.8)
Agoraphobia 5 (6.2) 6 (7.5)
Panic disorder 4 (4.9) 7 (8.8)
Social phobia 4 (4.9) 5 (6.3)
Psychotic disorder 3 (3.7) 3 (3.8)
Obsessive-compulsive disorder 1 (1.2) 8 (10.0)
Neurosis 1 (1.2) 2 (2.5)patients, adverse events considered at least possibly related
to study drug with a rate of ≥5% were dysgeusia (42.9%) in
the 2-mg group and dysgeusia (57.1%) and somnolence
(7.8%) in the 3-mg group. Nasopharyngitis, occurred in
20% of elderly patients and 22% of nonelderly patients but
was judged by the investigators to have no causal relation-
ship with eszopiclone administration in all cases.
Most adverse events were rated by the investigator as
mild or moderate in severity; adverse events rated as se-
vere occurred in 2.5% (2 of 81) of elderly patients in the
1-mg group and 0.0% (0 of 83) in the 2-mg group. Se-
vere adverse events that occurred in the 1-mg group
included sick sinus syndrome and loss of consciousness
in 1 patient and major depressive disorder in a second
patient. For nonelderly patients, adverse events rated as
severe occurred in 1.2% (1 of 84) of patients in the 2-mg
group and 2.6% (2 of 77) in the 3-mg group. Severe ad-
verse events that occurred in nonelderly patients were
acute myocardial infarction and heat illness, each occur-
ring in 1 patient in the 2-mg group, and atopic derma-
titis occurring in 1 patient in the 3-mg group. In
addition, there was 1 completed suicide, noted below as
a serious adverse event (SAE). In both elderly and none-
lderly patients, all severe adverse events were considered
by the investigator to be unrelated to study drug.
Twelve SAEs occurred in 10 patients (7 events in 6
elderly patients and 5 events in 4 nonelderly patients),
Table 3 Concomitant medications
Concomitant Medication, n (%) Insomnia With Psychiatric Disorders Insomnia Without Psychiatric Disorders
Elderly Nonelderly Elderly Nonelderly
(n = 81) (n = 80) (n = 83) (n = 81)
Psychoneurotic 47 (58.0) 52 (65.0) 8 (9.6) 4 (4.9)
Sedative, anxiolytic 31 (38.3) 30 (37.5) 7 (8.4) 3 (3.7)
Antipeptic ulcer 31 (38.3) 19 (23.8) 17 (20.5) 11 (13.6)
Analgesic, antipruritic, astringent, anti-inflammatory 29 (35.8) 15 (18.8) 28 (33.7) 10 (12.3)
Antihyperlipidemic agents 27 (33.3) 5 (6.3) 25 (30.1) 8 (9.9)
Antihypertensive agents 27 (33.3) 1 (1.3) 25 (30.1) 10 (12.3)
Vasodilators 23 (28.4) 3 (3.8) 20 (24.1) 7 (8.6)
Antipyretic, analgesic,anti-inflammatory 21 (25.9) 22 (27.5) 22 (26.5) 21 (25.9)
Cold and cough preparations 10 (12.3) 14 (17.5) 9 (10.8) 6 (7.4)
Other anti-allergy 8 (9.9) 14 (17.5) 10 (12.0) 4 (4.9)
Oriental medicines 18 (22.2) 9 (11.3) 16 (19.3) 8 (9.9)
Expectorant 7 (8.6) 5 (6.3) 13 (15.7) 10 (12.3)
Antitussive 6 (7.4) 6 (7.5) 11 (13.3) 8 (9.9)
Antibioticsa 9 (11.1) 8 (10.0) 9 (10.8) 8 (9.9)
a Acting mainly on gram-positive and gram-negative bacteria.
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to study drug. Among elderly patients, SAEs were
reported in 3 patients in the 1-mg group with psychiatric
disorders (aggravated type 1 diabetes mellitus in 1 pa-
tient, aggravated major depressive disorder in 1 patient,
and both sick sinus syndrome and loss of consciousness
in 1 patient), 1 patient in the 2-mg group with psychi-
atric disorders (oesophagitis haemorrhagic), and 2
patients in the 2-mg group without psychiatric disorders
(angina pectoris in 1 patient, and left calculus ureteric in
another patient). In nonelderly patients, SAEs other than
death occurred in 2 patients in the 2-mg group withTable 4 Adverse events occurring in ≥2% of patients in eithe







Upper respiratory tract infection 4 (4.9)
Back pain 4 (4.9)
Blood creatine phosphokinase increased 4 (4.9)
Thirst 3 (3.7)
Glucose urine present 3 (3.7)
Dizziness 1 (1.2)
Pharyngitis 1 (1.2)psychiatric disorders (appendicitis in 1 patient and acute
myocardial infarction and heat illness in another patient)
and in 1 patient in the 3-mg group without psychiatric
disorders (left clavicle fracture). There was 1 death dur-
ing the study; a 31-year-old man in the 3-mg group with
psychiatric disorders died by suicide 22 days after the
start of treatment. In addition to insomnia, the patient
had depression, dysthymia, irritable bowel syndrome,
and hepatic stenosis.
There were no clinically important changes from base-
line in vital signs or laboratory parameters in nonelderly
or elderly patients. Abnormal changes in ECG were notr age group
erly Nonelderly
2 mg 2 mg 3 mg
(n = 83) (n = 84) (n = 77)
23 (27.7) 36 (42.9) 44 (57.1)
18 (21.7) 22 (26.2) 14 (18.2)
5 (6.0) 3 (3.6) 1 (1.3)
2 (2.4) 3 (3.6) 6 (7.8)
3 (3.6) 2 (2.4) 4 (5.2)
3 (3.6) 2 (2.4) 1 (1.3)
1 (1.2) 3 (3.6) 2 (2.6)
0 (0.0) 2 (2.4) 2 (2.6)
2 (2.4) 1 (1.2) 1 (1.3)
4 (4.8) 0 (0.0) 1 (1.3)
2 (2.4) 3 (3.6) 1 (1.3)
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2.5% of elderly patients (2 of 79) in the 1-mg group and
in 1.2% (1 of 83) in the 2-mg group.
Based on the Questionnaire of Drug Dependence,
there was no evidence of psychological or physical drug
dependency in any of the treatment groups. Further-
more, there were no significant differences in depend-
ency questionnaire findings between treatment groups.
Efficacy
Self-report sleep diary
Eighty-eight percent of elderly patients and 83% of none-
lderly patients reported improvement in both SL and
TST at Week 4 compared with baseline. SL and TST
outcomes were similar in those with versus those with-
out comorbid psychiatric disorders. Eszopiclone 1 mg
and 2 mg significantly decreased median SL from 60
minutes at baseline to 20 or 30 minutes at Week 1 in
elderly insomnia patients with and without psychiatric
disorders, and the effects were sustained through Week
4 (P< 0.001 for all comparisons) (Figures 3A and 3B).
Similarly, eszopiclone 2 mg and 3 mg significantly
improved SL in nonelderly patients with and without
psychiatric disorders at all assessment points (Weeks 1,
2, 3, and 4; P< 0.001 for all comparisons) (Figures 3C
and 3D).Figure 3 Median values for sleep latency at baseline and at Weeks 1
obtained in elderly patients receiving eszopiclone 1 mg (A) or 2 mg (B) and
*P< 0.001 versus baseline for all treatment groups at all time points.In elderly and nonelderly insomnia patients, both with
and without psychiatric disorders, TST was significantly
greater at Week 1 than at baseline, and the increased
TST persisted through Week 4 (P< 0.001 for all com-
parisons; Figure 4). There were no statistically significant
differences between dose groups on prespecified
ANOVA models of SL or TST at any time point.
Measures of WASO and NA at Weeks 1 to 4 were sig-
nificantly improved from baseline for all patient sub-
groups (P< 0.05 for all comparisons). In addition,
quality of sleep (P< 0.05 for all comparisons) and depth
of sleep (P< 0.05 for all comparisons) at Weeks 1 to 4
were also significantly improved from baseline for all pa-
tient subgroups. Inter-group comparisons (1 mg vs 2 mg
in the elderly; 2 mg vs 3 mg in the nonelderly) revealed
no significant differences between different doses on
ANOVA models of WASO and NA at all assessment
points (Weeks 1 to 4).
In both elderly and nonelderly patients, significant im-
provement in self-reported daytime sleepiness and day-
time ability to function were observed at all assessment
points during the first treatment period (P< 0.01 for all
comparisons, elderly patients; P< 0.05 for all compari-
sons, nonelderly patients). Significant improvements (P
< 0.05) from baseline in daytime sleepiness and daytime
ability to function were observed in paired t-tests for thethrough 4. Median sleep latency (baseline; Week 1 through 4) were
in nonelderly patients receiving eszopiclone 2 mg (C) or 3 mg (D).
Figure 4 Median values for total sleep time at baseline and at Weeks 1 through 4. Median total sleep time (baseline; Weeks 1 through 4)
were obtained in elderly patients receiving eszopiclone 1 mg (A) or 2 mg (B) and in nonelderly patients receiving eszopiclone 2 mg (C) or 3 mg
(D). *P< 0.001 versus baseline for all treatment groups at all time points.
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and nonelderly patients with and without psychiatric dis-
orders, with the exception of daytime sleepiness in none-
lderly patients with psychiatric disorders in the 3-mg
group who experienced small but not statistically signifi-
cant improvement.
Judgment of dose increase and efficacy at week 24
The investigators evaluated the appropriateness of dose
escalation per patient for the second treatment period in
a double-blind manner based on the criteria described in
the study procedures. As a result, 6 patients in the eld-
erly group and 11 patients in the nonelderly group were
confirmed to be eligible for 1-mg uptitration (Table 5).
Of these patients, 4 elderly patients receiving 1 mg eszo-
piclone and 7 nonelderly patients receiving 2 mg eszopi-
clone underwent uptitration (1 mg), whereas other
patients who had been treated with higher doses in each
group received a placebo tablet (ie, alternative to 1 mg
eszopiclone) in addition to their current assigned treat-
ment for the second treatment period.
At Week 24 (LOCF), significant improvement from
baseline was noted for all patient subgroups in SL (Fig-
ure 5) and TST (nonelderly patients: median change of
+60.0 min and +50.0 min for eszopiclone 2 mg and
3 mg, respectively; elderly patients: median change of
+60.0 min and +70.0 for eszopiclone 1 mg and 2 mg; P< 0.001 for all comparisons). Similarly, WASO, NA,
quality of sleep, and depth of sleep were significantly
improved in all patient subgroups (P< 0.01 for all com-
parisons). For measures of daytime sleepiness and day-
time ability to function, improvement was significant
(P< 0.05) for all subgroups, with the exception of small
but not statistically significant improvement in daytime
sleepiness among nonelderly patients with psychiatric
disorders receiving 3 mg eszopiclone. There was no ap-
parent evidence of rebound insomnia following eszopi-
clone discontinuation (Table 6). Significant improvement
from baseline in SL was maintained during the follow-
up period in all subgroups at all assigned doses of eszo-
piclone (P< 0.05 for all comparisons; Figure 5). During
the follow-up period, TST and WASO demonstrated im-
provement or maintained the same status compared
with baseline in both elderly and nonelderly patients, re-
gardless of psychiatric comorbidity status.
Short-form 36
Baseline scores for the Physical Component Summary of
the SF-36 in elderly patients with psychiatric disorders
were poor (40.9 and 41.1 for 1 mg and 2 mg, respect-
ively; Table 7). Scores in nonelderly patients with and
without psychiatric disorders and in elderly insomnia
patients without psychiatric disorders ranged from 46.8
to 51.7. Eszopiclone did not significantly alter the
Table 5 Judgment regarding 1 mg uptitration at Week 4
Dose in First Treatment Period, Subgroup (n) Improved SL and TST at Week 4, n (%) Not Eligible, n Eligiblea, n
Elderly
1 mg, with psychiatric disorders (n = 34) 29 (85.3) 32 2
2 mg, with psychiatric disorders (n = 42) 39 (92.9) 41 1
1 mg, without psychiatric disorders (n = 40) 34 (85.0) 38 2
2 mg, without psychiatric disorders (n = 36) 32 (88.9) 35 1
Total elderly (n = 152) 134 (88.2) 146 6
Nonelderly
2 mg, with psychiatric disorders (n = 41) 36 (87.8) 39 2
3 mg, with psychiatric disorders (n = 35) 28 (80.0) 32 3
2 mg, without psychiatric disorders (n = 41) 31 (75.6) 36 5
3 mg, without psychiatric disorders (n = 38) 33 (86.8) 37 1
Total nonelderly (n = 155) 128 (82.6) 144 11
a Patients in the elderly 2-mg group and the nonelderly 3-mg group for whom dose escalation would be appropriate were given a 1-mg placebo tablet.
SL = sleep latency; TST = total sleep time.
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(Table 7).
Baseline scores for the Mental Component Summary
in both elderly and nonelderly insomnia patients with
psychiatric disorders were 38.3 to 44.7 (Table 7), which
is below the Japanese national standard value of 50Figure 5 Median values for sleep latency at baseline, Week 24, and W
obtained in elderly patients receiving eszopiclone 1 mg (A) or 2 mg (B) and
For the patients who discontinued study treatment, data at final administra
after final administration of study drug were handled as Week 25 data (last
†P< 0.05 versus baseline; {P< 0.01 versus baseline.points. Eszopiclone significantly improved Mental Com-
ponent Summary scores by 4.3 to 6.8 at final visit (P
< 0.01 for all comparisons; Table 7). Mental Component
Summary scores in elderly and nonelderly insomnia
patients without psychiatric disorders were 49.4 to 55.3
at baseline and either slightly improved with eszopicloneeek 25. Median sleep latency (baseline; Weeks 24 and 25) were
in nonelderly patients receiving eszopiclone 2 mg (C) or 3 mg (D).
tion of study drug were handled as Week 24 data, and data at 1 week
observation carried forward [LOCF]). *P< 0.001 versus baseline;
Table 6 Sleep variables at baseline and Week 25 (after discontinuation of eszopiclone)
Measure Elderly Elderly Nonelderly Nonelderly
1 mg 2 mg 2 mg 3 mg
Baseline Week 25 Baseline Week 25 Baseline Week 25 Baseline Week 25
Sleep latency, min n = 80 n= 74 n= 83 n= 78 n= 84 n= 71 n= 77 n= 62
Mean (SD) 67.8 (42.3) 50.8 (47.8) 76.2 (48.9) 70.7 (81.2) 75.5 (51.3) 65.4 (67.3) 70.8 (46.4) 61.5 (66.3)
Median 60.0 30.0 60.0 40.0 60.0 40.0 60.0 30.0
Total sleep time, min n = 80 n= 74 n= 83 n= 78 n= 84 n= 71 n= 77 n= 62
Mean (SD) 311.0 (68.9) 340.0 (96.3) 299.3 (59.8) 328.7 (102.3) 282.0 (47.7) 315.3 (61.1) 312.4 (67.1) 336.3 (80.6)
Median 330.0 360.0 300.0 360.0 290.0 300.0 300.0 337.5
Wake time after sleep onset,
min n = 79 n= 74 n= 82 n= 77 n= 84 n= 71 n= 77 n= 62
Mean (SD) 70.8 (57.8) 46.0 (49.1) 77.2 (64.8) 50.8 (53.3) 70.3 (65.5) 28.0 (32.6) 50.2 (42.0) 35.7 (54.0)
Median 60.0 30.0 60.0 30.0 60.0 15.0 45.0 15.0
Number of awakenings n = 80 n= 74 n= 83 n= 77 n= 84 n= 71 n= 77 n= 62
Mean (SD) 2.1 (0.9) 1.6 (1.0) 2.2 (1.0) 2.0 (1.1) 1.9 (1.0) 1.2 (1.0) 1.9 (1.4) 1.7 (1.7)
Median 2.0 2.0 2.0 2.0 2.0 1.0 2.0 1.0
Quality of sleep * n = 80 n= 74 n= 83 n= 78 n= 84 n= 71 n= 77 n= 62
Mean (SD) 4.1 (1.8) 5.4 (2.3) 4.2 (1.8) 5.3 (2.5) 3.4 (1.2) 4.5 (2.2) 4.1 (1.7) 4.8 (2.8)
Median 4.0 5.0 4.0 5.0 3.0 4.0 4.0 5.0
Depth of sleep * n = 80 n= 74 n= 83 n= 78 n= 84 n= 71 n= 77 n= 62
Mean (SD) 4.2 (1.9) 5.4 (2.3) 4.3 (2.1) 5.1 (2.6) 3.3 (1.2) 4.7 (2.1) 4.1 (1.8) 4.8 (2.7)
Median 4.0 5.0 4.0 5.0 3.0 4.0 4.0 5.0
Daytime sleepiness * n = 80 n= 74 n= 83 n= 78 n= 84 n= 71 n= 77 n= 62
Mean (SD) 5.1 (2.2) 6.2 (2.3) 5.0 (1.9) 6.0 (2.4) 4.1 (1.7) 4.9 (2.3) 4.7 (2.1) 5.5 (2.6)
Median 5.0 6.0 5.0 6.0 4.0 5.0 5.0 6.0
Daytime ability to function * n = 80 n= 74 n= 83 n= 78 n= 84 n= 71 n= 77 n= 62
Mean (SD) 5.6 (2.1) 6.7 (2.1) 5.6 (2.0) 6.4 (2.2) 4.5 (1.7) 5.6 (2.1) 4.9 (1.9) 5.9 (2.5)
Median 5.5 7.0 5.0 7.0 4.5 5.0 5.0 6.0
*: Assessed based on a numeric rating scale (0–10 scale, with higher values indicating more positive outcomes).
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tal health domain is 1of 8 SF-36 domains and is also 1of
5 components of the Mental Component Summary.
Changes in mental health domain scores from baseline
to final visit showed a similar tendency as the Mental
Component Summary scores (Table 7).
Discussion
This study in Japanese elderly and nonelderly adults with
chronic insomnia, with and without comorbid psychi-
atric disorders, extended the favorable safety and toler-
ability profile of eszopiclone. The inclusion/exclusion
criteria for this study were generally similar to criteria
used in US studies [9-13,15-20]. The principal difference
is that this Japanese study was heterogeneous in terms
of age range and insomnia subtype, whereas separate US
studies were used to evaluate elderly or non-elderly
patients and patients with primary or comorbidinsomnia [9-13,15-20]. In the present study, the most
frequently reported adverse event was dysgeusia, which
is a characteristic adverse event associated with eszopi-
clone treatment. Overall, the rates of adverse events that
led to discontinuation of study treatment were relatively
low, and no unexpected adverse events were noted from
a safety viewpoint.
Eszopiclone significantly improved sleep variables (SL,
TST, WASO, NA, sleep quality, and sleep depth) and
daytime activity in elderly and nonelderly patients both
with and without psychiatric disorders. These improve-
ments were observed in the first week after initiating
treatment with eszopiclone and were maintained over
4 weeks of treatment. There was no evidence of daytime
impairment, and the numeric rating scale scores gener-
ally indicated subjective improvement from baseline in
daytime sleepiness and daytime functioning. Otherwise,
the benefits of eszopiclone related to sleep parameters
Table 7 Change in SF-36 scores from baseline to final visit
Dose, Subgroup (n at final visit) Physical Component Summary Mental Component Summary Mental Health Domain
Elderly
1 mg, with psychiatric disorders (n = 37)a
Baseline 40.9 (15.9) 43.6 (9.9) 39.5 (12.2)
Final visit (LOCF) 42.4 (12.2) 50.8 (10.9) 47.3 (11.2)
Change from baseline 1.5 (10.4) 6.8 (11.2)* 7.3 (12.0)*
2 mg, with psychiatric disorders (n = 42)
Baseline 41.1 (15.7) 44.7 (10.6) 41.5 (13.2)
Final visit (LOCF) 43.3 (12.4) 50.5 (9.0) 47.0 (11.3)
Change from baseline 2.3 (10.6) 5.8 (8.4)* 5.5 (8.8)*
1 mg, without psychiatric disorders (n = 42)
Baseline 46.8 (10.3) 54.7 (7.2) 53.7 (8.7)
Final visit (LOCF) 48.4 (7.4) 57.5 (6.8) 57.0 (7.2)
Change from baseline 1.6 (7.0) 2.9 (7.2)† 3.3 (8.2)†
2 mg, without psychiatric disorders (n = 41)
Baseline 51.7 (5.0) 55.3 (7.9) 54.6 (7.7)
Final visit (LOCF) 51.5 (6.2) 56.1 (7.4) 55.7 (7.0)
Change from baseline −0.2 (5.3) 0.8 (7.5) 1.1 (8.7)
Nonelderly
2 mg, with psychiatric disorders (n = 43)
Baseline 47.1 (10.4) 38.3 (8.7) 37.7 (9.1)
Final visit (LOCF) 47.5 (9.8) 44.6 (9.7) 43.6 (10.1)
Change from baseline 0.4 (10.5) 6.3 (9.3)* 5.9 (9.8)*
3 mg, with psychiatric disorders (n = 36)a
Baseline 49.4 (8.8) 39.8 (8.2) 39.5 (6.9)
Final visit (LOCF) 49.5 (11.0) 44.2 (8.3) 44.4 (10.1)
Change from baseline −0.1 (8.9) 4.3 (9.2){ 4.8 (11.3)†
2 mg, without psychiatric disorders (n = 41)
Baseline 50.6 (8.0) 49.8 (7.6) 50.1 (9.1)
Final visit (LOCF) 51.7 (9.7) 50.8 (9.2) 50.7 (10.5)
Change from baseline 1.2 (8.6) 1.0 (9.6) 0.7 (12.0)
3 mg, without psychiatric disorders (n = 39)a
Baseline 50.9 (11.4) 49.4 (7.9) 50.4 (7.8)
Final visit (LOCF) 52.5 (8.1) 51.2 (8.1) 51.9 (7.8)
Change from baseline 1.7 (10.8) 1.7 (5.9) 1.6 (7.3)
All values represent mean (SD). Norm-based scorings (50 points represents the mean national standard value of Japanese people, with a standard deviation of 10).
a 1 discontinuation.
*P< 0.001, †P< 0.05, {P< 0.01.
LOCF = last observation carried forward; SD= standard deviation.
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lderly patients. Efficacy evaluations were performed at
Week 24 as part of the assessment of rebound insomnia
and demonstrated that improvements in sleep and day-
time functioning were maintained over 24 weeks of
treatment. No rebound insomnia was observed after dis-
continuation of eszopiclone treatment. These observa-
tions confirm that the benefits of eszopiclone reportedin US clinical studies of nonelderly [9-11] and elderly
[12,13] patients with chronic insomnia (improvements
in SL, TST, WASO, NA, sleep quality, sleep depth, and
daytime activity) apply to the Japanese population.
The pharmacokinetics of eszopiclone have previously
been compared in Japanese and Caucasian healthy adult
and elderly subjects (unpublished data). The results
showed that the pharmacokinetic and safety profiles of
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the Caucasian population (unpublished data). Therefore,
it is anticipated that ethnic factors are unlikely to influ-
ence the pharmacokinetics, efficacy, and safety of eszopi-
clone. In the current study, there was a lack of dose
differentiation between 1-mg and 2-mg eszopiclone in
elderly patients and between 2 mg and 3 mg eszopiclone
in nonelderly patients with regard to all sleep studies
(Weeks 1 to 4). These observations differ from the dose
responses observed in US studies [9,11,13]. A 2-week
study of eszopiclone in elderly patients with chronic in-
somnia reported that the higher dose (2 mg) significantly
improved SL, TST, WASO, quality of sleep, and depth of
sleep relative to placebo, but the lower dose (1 mg)
improved SL but not TST, WASO, quality of sleep, or
depth of sleep versus placebo [13]. Similarly, in the 6-
week study of eszopiclone (2 mg and 3 mg versus pla-
cebo) in nonelderly adults with chronic insomnia, both
doses improved SL and TST, but the 2-mg dose did not
improve WASO [9]. This finding is supported by a poly-
somnography crossover study in nonelderly adults that
demonstrated improvement in WASO with eszopiclone
3 mg but not 2 mg [11]. The reasons underlying the ap-
parent difference in dose-responsiveness between Japa-
nese and US populations are not well understood. The
heterogeneous patient population in this study, which
included both patients with primary and comorbid in-
somnia, does not seem to be an explanatory factor. In
US studies, eszopiclone was effective for sleep induction
and maintenance at the same dose (3 mg for non-elderly
patients, 2 mg for elderly patients) regardless of the
presence of psychiatric comorbidity [9-13,15,16,18-20].
Insomnia commonly presents comorbidly with psychi-
atric disorders, particularly anxiety disorders and depres-
sion [23-26]. Recent studies have shown that eszopiclone
improves both sleep variables and psychiatric symptoms
in nonelderly insomnia patients with depression receiv-
ing fluoxetine [19], and patients with generalized anxiety
disorder receiving escitalopram oxalate [20]. The current
study examined the mental and physical health effects of
long-term eszopiclone treatment in elderly and none-
lderly insomnia patients with or without a psychiatric
disorder. Eszopiclone significantly improved Mental
Component Summary scores on the SF-36 among eld-
erly and nonelderly patients with comorbid psychiatric
illness; median scores were below the national standard
value at baseline and increased to approximately the na-
tional standard level following treatment. Further, eszo-
piclone produced statistically significant improvement
on the Mental Health Domain among patients with psy-
chiatric comorbidities, and the 1-mg dose of eszopiclone
also significantly improved Mental Health Domain
scores among elderly patients without comorbid psychi-
atric illness. These findings suggest that eszopiclone canimprove quality of life in patients with insomnia asso-
ciated with a psychiatric disorder.
A limitation of the current study was that it was not
placebo- or active-controlled. As discussed earlier, inclu-
sion of a placebo arm was considered unacceptable be-
cause of the long-term nature of the study and the
presumed distress associated with untreated insomnia,
particularly in patients with comorbid psychiatric or
physical disorders. However, the lack of a placebo group
limits the strength of conclusions regarding the efficacy
of eszopiclone and the absence of a rebound effect. In
addition, statistical tests comparing Week 24 and 25
were not performed; it is therefore difficult to assess
changes in sleep parameters upon discontinuation of
eszopiclone. Also, the potential effects of dose escalation
on efficacy of eszopiclone could not be adequately
assessed, because an increased dose was needed by only
a small proportion of patients in the study. Furthermore,
the ability to generalize results from this study to the
general Japanese population is limited by the exclusion
of patients with certain disorders (eg, PTSD, history of
drug abuse, or medication-related insomnia). Although
use of medications with the potential to modify sleep
was restricted until the primary efficacy evaluation at
Week 4, some potentially sedating drugs (eg, anxiolytics
not indicated for insomnia) were permitted after Week 4
and may have affected subsequent assessments of the ef-
ficacy and tolerability of eszopiclone. Other limitations
include the lack of polysomnographic recording of sleep
parameters and objective assessment of daytime func-
tioning, cognitive function, and behavioral adverse
effects (eg, potential carryover sedation), which may
have been more sensitive ways of assessing for potential
dose response effects of eszopiclone in this population.
Conclusions
In conclusion, 24 weeks of treatment with eszopiclone in
Japanese elderly and nonelderly patients with chronic in-
somnia was shown to be safe and well tolerated, with no
evidence of rebound insomnia or dependency following
discontinuation. Results of this study demonstrate bene-
fits of eszopiclone on sleep variables in a clinically repre-
sentative sample of the Japanese population. Further,
this study shows for the first time that benefits are main-
tained over 24 weeks in both elderly and nonelderly
patients, as well as in patients with and without comor-
bid psychiatric disorders. The safety of eszopiclone and
effects on sleep variables and daytime activity are con-
sistent with what was observed in the US pivotal studies.
In contrast to US studies, there was no apparent differ-
ence between the lower (1 mg in elderly patients, 2 mg
in nonelderly patients) and higher (2 mg in elderly
patients, 3 mg in nonelderly patients) eszopiclone doses
in the Japanese patients, suggesting that it is rational to
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in nonelderly patients) and titrate upward if needed.
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